Liver metastasis of pancreatic cancer: the new choice at the crossroads.
作者信息
Liu Zhe, Gou Anjiang, Wu Xingda
机构信息
Department of Pancreatic-Biliary Surgery, The First Hospital of China Medical University, Shenyang, China.
出版信息
Hepatobiliary Surg Nutr. 2023 Feb 28;12(1):88-91. doi: 10.21037/hbsn-22-489. Epub 2023 Jan 16.
Abstract
摘要
相似文献
1
Liver metastasis of pancreatic cancer: the new choice at the crossroads.胰腺癌肝转移：十字路口的新选择
Hepatobiliary Surg Nutr. 2023 Feb 28;12(1):88-91. doi: 10.21037/hbsn-22-489. Epub 2023 Jan 16.
2
Two Novel Nomograms Predicting the Risk and Prognosis of Pancreatic Cancer Patients With Lung Metastases: A Population-Based Study.两种预测肺转移胰腺癌患者风险和预后的新型列线图：基于人群的研究。
Front Public Health. 2022 May 31;10:884349. doi: 10.3389/fpubh.2022.884349. eCollection 2022.
3
[Treatments for Pancreatic Cancer with Oligometastasis].[寡转移胰腺癌的治疗]
Gan To Kagaku Ryoho. 2017 Oct;44(10):827-830.
4
Solitary prostate cancer liver metastasis: an exceptional indication for liver resection.孤立性前列腺癌肝转移：肝切除术的一个特殊适应证。
Acta Chir Belg. 2021 Dec;121(6):427-431. doi: 10.1080/00015458.2020.1722929. Epub 2020 Feb 11.
5
[Surgical treatment for pancreatic cancer with liver metastasis:exploration and innovation].[胰腺癌肝转移的外科治疗：探索与创新]
Zhonghua Wai Ke Za Zhi. 2021 Jul 1;59(7):593-596. doi: 10.3760/cma.j.cn112139-20210406-00161.
6
Surgical and local treatment of hepatic metastasis in pancreatic ductal adenocarcinoma: recent advances and future prospects.胰腺导管腺癌肝转移的手术及局部治疗：最新进展与未来展望
Ther Adv Med Oncol. 2020 Jun 23;12:1758835920933034. doi: 10.1177/1758835920933034. eCollection 2020.
7
Risk factors, prognostic predictors, and nomograms for pancreatic cancer patients with initially diagnosed synchronous liver metastasis.初诊为同时性肝转移的胰腺癌患者的危险因素、预后预测指标及列线图
World J Gastrointest Oncol. 2023 Jan 15;15(1):128-142. doi: 10.4251/wjgo.v15.i1.128.
8
Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1).胰腺癌伴肝脏寡转移患者经转化化疗后同期切除原发灶和肝转移灶与标准治疗的对比：一项多中心、前瞻性、随机对照 III 期临床试验（CSPAC-1）方案。
BMJ Open. 2019 Dec 8;9(12):e033452. doi: 10.1136/bmjopen-2019-033452.
9
Outcomes of pancreatic cancer with liver oligometastasis.肝寡转移胰腺癌的预后。
J Hepatobiliary Pancreat Sci. 2023 Feb;30(2):229-239. doi: 10.1002/jhbp.1184. Epub 2022 Jun 1.
10
Hepatic Artery Infusion of Floxuridine in Combination With Systemic Chemotherapy for Pancreatic Cancer Liver Metastasis: A Propensity Score-Matched Analysis in Two Centers.氟尿苷肝动脉灌注联合全身化疗治疗胰腺癌肝转移：两个中心的倾向评分匹配分析
Front Oncol. 2021 Apr 28;11:652426. doi: 10.3389/fonc.2021.652426. eCollection 2021.
引用本文的文献
1
Stromal softness confines pancreatic cancer growth through lysosomal-cathepsin mediated YAP1 degradation.基质柔软度通过溶酶体组织蛋白酶介导的 YAP1 降解限制胰腺癌生长。
Cell Mol Life Sci. 2024 Oct 26;81(1):442. doi: 10.1007/s00018-024-05466-y.
2
The impact of metastatic sites on survival Rates and predictors of extended survival in patients with metastatic pancreatic cancer.转移性部位对转移性胰腺癌患者生存率的影响及延长生存的预测因素。
Pancreatology. 2024 Sep;24(6):887-893. doi: 10.1016/j.pan.2024.06.004. Epub 2024 Jun 12.
3
Editorial: Novel immunological characteristics and immunotherapeutic targets in pancreatic cancer.社论：胰腺癌的新型免疫特征及免疫治疗靶点
Front Immunol. 2024 Jun 3;15:1428740. doi: 10.3389/fimmu.2024.1428740. eCollection 2024.
4
Principles of Palliative and Supportive Care in Pancreatic Cancer: A Review.胰腺癌姑息与支持治疗原则：综述
Biomedicines. 2023 Oct 1;11(10):2690. doi: 10.3390/biomedicines11102690.
本文引用的文献
1
The Liver Pre-Metastatic Niche in Pancreatic Cancer: A Potential Opportunity for Intervention.胰腺癌中的肝脏前转移生态位：一个潜在的干预机会。
Cancers (Basel). 2022 Jun 20;14(12):3028. doi: 10.3390/cancers14123028.
2
Molecular characterization of circulating tumor cells in pancreatic ductal adenocarcinoma: potential diagnostic and prognostic significance in clinical practice.胰腺导管腺癌循环肿瘤细胞的分子特征：临床实践中的潜在诊断和预后意义。
Hepatobiliary Surg Nutr. 2021 Dec;10(6):796-810. doi: 10.21037/hbsn-20-383.
3
Perioperative immunotherapy for pancreatic cancer is on its way.胰腺癌的围手术期免疫疗法正在兴起。
Hepatobiliary Surg Nutr. 2021 Aug;10(4):534-537. doi: 10.21037/hbsn-21-238.
4
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.胰腺导管腺癌临床实践指南（第 2.2021 版），NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2021 Apr 1;19(4):439-457. doi: 10.6004/jnccn.2021.0017.
5
Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment.外泌体递送的 CD44v6/C1QBP 复合物通过促进纤维性肝微环境促进胰腺癌肝转移。
Gut. 2022 Mar;71(3):568-579. doi: 10.1136/gutjnl-2020-323014. Epub 2021 Apr 7.
6
Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic ductal adenocarcinoma.整合基因组和转录组分析揭示了胰腺导管腺癌肝转移的独特特征和补体 C1q 的促转移作用。
Genome Biol. 2021 Jan 4;22(1):4. doi: 10.1186/s13059-020-02222-w.
7
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.奈达铂联合吉西他滨治疗局部晚期胰腺癌（LAPACT）的多中心、开放标签、2 期研究。
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):285-294. doi: 10.1016/S2468-1253(19)30327-9. Epub 2020 Jan 14.
8
Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection.肝寡转移型胰体尾部导管腺癌患者可能从同步切除中获益。
HPB (Oxford). 2020 Jan;22(1):91-101. doi: 10.1016/j.hpb.2019.05.015. Epub 2019 Jun 29.
9
Exosome-Mediated Metastasis: Communication from a Distance.外泌体介导的转移：远程通讯。
Dev Cell. 2019 May 6;49(3):347-360. doi: 10.1016/j.devcel.2019.04.011.
10
Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer.基质蛋白βig-h3 重编程胰腺癌中的肿瘤微环境。
Gut. 2019 Apr;68(4):693-707. doi: 10.1136/gutjnl-2018-317570. Epub 2018 Nov 10.
Zotero 插件